INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 45h ago
HOUSE PTR5h ago
SEC 13F5h ago
ROBINHOOD CHAIN5h ago
Public company

TENXTENAX THERAPEUTICS, INC.

CIK 0000034956

EDGAR filingsOpen in network
Disclosed transactions24
Buys / sells20 / 0
Max Insider Score52
Connections7with evidence

TENX · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
32
AM
ADAR1 Capital Management, LLC10% Owner
TENXTENAX THERAPEUTICS, INC.
Open-market purchase
BUY$507K
336.5K sh
Oct 19, 2026Oct 21, 2026
traded Oct 19, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2834 · Pharmaceutical Preparations · Nov 4, 2026
  • ← Insider ofevidence
    ADAR1 Capital Management, LLC10% Owner · Aug 24, 2026
  • ← Insider ofevidence
    Schneeberger Daniel10% Owner · Aug 24, 2026
  • ← Insider ofevidence
    Hunter RobynDirector · Jan 13, 2026
28
AM
ADAR1 Capital Management, LLC10% Owner
TENXTENAX THERAPEUTICS, INC.
Open-market purchase
BUY
$551K
332.0K sh
Oct 21, 2026
Oct 21, 2026
traded Oct 21, 2026
+0d
SEC FORM 4

Evidence

28
AM
ADAR1 Capital Management, LLC10% Owner
TENXTENAX THERAPEUTICS, INC.
Open-market purchase
BUY$406K
254.3K sh
Oct 20, 2026Oct 21, 2026
traded Oct 20, 2026
+1dSEC FORM 4

Evidence

38
GT
Giordano Christopher ThomasDirector, CEO
TENXTENAX THERAPEUTICS, INC.
Open-market purchase
BUY$8,837
4,850 sh
Sep 15, 2026Sep 15, 2026
traded Sep 15, 2026
+0dSEC FORM 4

Evidence

42
GT
Giordano Christopher ThomasDirector, CEO
TENXTENAX THERAPEUTICS, INC.
Open-market purchase
BUY$11K
6,000 sh
Sep 11, 2026Sep 15, 2026
traded Sep 11, 2026
+4dSEC FORM 4

Evidence

46
AM
ADAR1 Capital Management, LLC10% Owner
TENXTENAX THERAPEUTICS, INC.
Open-market purchase
BUY$1.60M
900.0K sh
Sep 3, 2026Sep 8, 2026
traded Sep 3, 2026
+5dSEC FORM 4

Evidence

36
AM
ADAR1 Capital Management, LLC10% Owner
TENXTENAX THERAPEUTICS, INC.
Open-market purchase
BUY$322K
179.1K sh
Sep 1, 2026Sep 2, 2026
traded Sep 1, 2026
+1dSEC FORM 4

Evidence

36
AM
ADAR1 Capital Management, LLC10% Owner
TENXTENAX THERAPEUTICS, INC.
Open-market purchase
BUY$338K
187.7K sh
Sep 2, 2026Sep 2, 2026
traded Sep 2, 2026
+0dSEC FORM 4

Evidence

40
AM
ADAR1 Capital Management, LLC10% Owner
TENXTENAX THERAPEUTICS, INC.
Open-market purchase
BUY$723K
403.6K sh
Aug 31, 2026Sep 2, 2026
traded Aug 31, 2026
+2dSEC FORM 4

Evidence

38
AM
ADAR1 Capital Management, LLC10% Owner
TENXTENAX THERAPEUTICS, INC.
Open-market purchase
BUY$1.27M
716.4K sh
Aug 21, 2026Aug 24, 2026
traded Aug 21, 2026
+3dSEC FORM 4

Evidence

28
AM
ADAR1 Capital Management, LLC10% Owner
TENXTENAX THERAPEUTICS, INC.
Open-market purchase
BUY$188K
107.4K sh
Aug 24, 2026Aug 24, 2026
traded Aug 24, 2026
+0dSEC FORM 4

Evidence

39
AM
ADAR1 Capital Management, LLC10% Owner
TENXTENAX THERAPEUTICS, INC.
Open-market purchase
BUY$360K
202.1K sh
Aug 20, 2026Aug 24, 2026
traded Aug 20, 2026
+4dSEC FORM 4

Evidence

5
RS
Rich StuartDirector, Chief Medical Officer
TENXTENAX THERAPEUTICS, INC.
Grant or award
A—
250.0K sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

9
DD
Doogan DeclanDirector
TENXTENAX THERAPEUTICS, INC.
Grant or award
A—
30.0K sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

9
HR
Hunter RobynDirector
TENXTENAX THERAPEUTICS, INC.
Grant or award
A—
30.0K sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

5
GT
Giordano Christopher ThomasDirector, CEO
TENXTENAX THERAPEUTICS, INC.
Grant or award
A—
450.0K sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

37
RS
Rich StuartDirector, Chief Medical Officer
TENXTENAX THERAPEUTICS, INC.
Open-market purchase
BUY$26K
2,500 sh
Dec 9, 2025Dec 10, 2025
traded Dec 9, 2025
+1dSEC FORM 4

Evidence

37
RS
Rich StuartDirector, Chief Medical Officer
TENXTENAX THERAPEUTICS, INC.
Open-market purchase
BUY$25K
2,500 sh
Dec 8, 2025Dec 10, 2025
traded Dec 8, 2025
+2dSEC FORM 4

Evidence

42
RS
Rich StuartDirector, Chief Medical Officer
TENXTENAX THERAPEUTICS, INC.
Open-market purchase
BUY$14K
1,500 sh
Dec 3, 2025Dec 5, 2025
traded Dec 3, 2025
+2dSEC FORM 4

Evidence

42
RS
Rich StuartDirector, Chief Medical Officer
TENXTENAX THERAPEUTICS, INC.
Open-market purchase
BUY$23K
2,500 sh
Dec 4, 2025Dec 5, 2025
traded Dec 4, 2025
+1dSEC FORM 4

Evidence

52
RS
Rich StuartDirector, Chief Medical Officer
TENXTENAX THERAPEUTICS, INC.
Open-market purchase
BUY$9,006
1,000 sh
Dec 2, 2025Dec 5, 2025
traded Dec 2, 2025
+3dSEC FORM 4

Evidence

38
GT
Giordano Christopher ThomasDirector, CEO
TENXTENAX THERAPEUTICS, INC.
Open-market purchase
BUY$3,417
455 sh
Nov 19, 2025Nov 20, 2025
traded Nov 19, 2025
+1dSEC FORM 4

Evidence

46
GT
Giordano Christopher ThomasDirector, CEO
TENXTENAX THERAPEUTICS, INC.
Open-market purchase
BUY$13K
1,612 sh
Nov 18, 2025Nov 20, 2025
traded Nov 18, 2025
+2dSEC FORM 4

Evidence

38
GT
Giordano Christopher ThomasDirector, CEO
TENXTENAX THERAPEUTICS, INC.
Open-market purchase
BUY$4,083
538 sh
Nov 20, 2025Nov 20, 2025
traded Nov 20, 2025
+0dSEC FORM 4

Evidence

← Insider ofevidence
Doogan Declan
Director · Jan 13, 2026
  • ← Insider ofevidence
    Rich StuartDirector, Chief Medical Officer · Dec 5, 2025
  • ← Insider ofevidence
    Giordano Christopher ThomasDirector, CEO · Nov 20, 2025